Tissue-based molecular markers for renal cell carcinoma
Standard
Tissue-based molecular markers for renal cell carcinoma. / Rink, M; Chun, F K H; Robinson, B; Sun, M; Karakiewicz, P I; Bensalah, K; Fisch, M; Scherr, D S; Lee, R K; Margulis, V; Shariat, S F.
in: MINERVA UROL NEFROL, Jahrgang 63, Nr. 4, 4, 12.2011, S. 293-308.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Tissue-based molecular markers for renal cell carcinoma
AU - Rink, M
AU - Chun, F K H
AU - Robinson, B
AU - Sun, M
AU - Karakiewicz, P I
AU - Bensalah, K
AU - Fisch, M
AU - Scherr, D S
AU - Lee, R K
AU - Margulis, V
AU - Shariat, S F
PY - 2011/12
Y1 - 2011/12
N2 - Since the introduction of targeted therapies in renal cell carcinoma (RCC), more individualized treatment options have become available. Molecular markers might support treatment planning due to more accurate individual risk stratification. Current molecular markers in RCC were reviewed to elucidate clinical impact and future perspectives. An English-language literature review of the Medline database (1990 to September 2010) of published data on tissue-based molecular markers and RCC was undertaken. Histological types, clinical and oncological behaviour are variable in renal masses. Molecular markers offer potential for additional information in tumour detection and diagnosis, prognostic and predictive values, as well as determination of therapeutic targets. Investigations on molecular biomarkers in RCC include hypoxia inducible factor (HIF-?), vascular endothelial growth factor (VEGF), carbonic anhydrase IX (CAIX), mammalian target of rapamycin (mTOR), survivin, B7-H1, p53, matrix metalloproteinases (MMP), Insulin-like growth factor II mRNA-binding protein 3 (IMP3), Ki-67, C-reactive protein (CRP), Vimentin, Fascin, platelet count, hemoglobin level and combinations of these factors. Although some markers offer promising results, utilization in daily practice is compromised due to limited specificity, predictive accuracy and tumour histology variablity. There is an imminent need for novel molecular markers that allow accurate histologic and biologic classification of RCC to improve upon current outcomes. It is very likely that a panel of molecular markers will be used to achieve a sufficient degree of certainty in order to guide clinical decisions. A large concerted effort is required to advance the field of RCC molecular marker through systematic discovery, verification, and validation.
AB - Since the introduction of targeted therapies in renal cell carcinoma (RCC), more individualized treatment options have become available. Molecular markers might support treatment planning due to more accurate individual risk stratification. Current molecular markers in RCC were reviewed to elucidate clinical impact and future perspectives. An English-language literature review of the Medline database (1990 to September 2010) of published data on tissue-based molecular markers and RCC was undertaken. Histological types, clinical and oncological behaviour are variable in renal masses. Molecular markers offer potential for additional information in tumour detection and diagnosis, prognostic and predictive values, as well as determination of therapeutic targets. Investigations on molecular biomarkers in RCC include hypoxia inducible factor (HIF-?), vascular endothelial growth factor (VEGF), carbonic anhydrase IX (CAIX), mammalian target of rapamycin (mTOR), survivin, B7-H1, p53, matrix metalloproteinases (MMP), Insulin-like growth factor II mRNA-binding protein 3 (IMP3), Ki-67, C-reactive protein (CRP), Vimentin, Fascin, platelet count, hemoglobin level and combinations of these factors. Although some markers offer promising results, utilization in daily practice is compromised due to limited specificity, predictive accuracy and tumour histology variablity. There is an imminent need for novel molecular markers that allow accurate histologic and biologic classification of RCC to improve upon current outcomes. It is very likely that a panel of molecular markers will be used to achieve a sufficient degree of certainty in order to guide clinical decisions. A large concerted effort is required to advance the field of RCC molecular marker through systematic discovery, verification, and validation.
KW - B7-H1 Antigen
KW - Biomarkers, Tumor
KW - C-Reactive Protein
KW - Carbonic Anhydrases
KW - Carcinoma, Renal Cell
KW - Carrier Proteins
KW - Cysteine Proteinase Inhibitors
KW - Hemoglobins
KW - Humans
KW - Hypoxia-Inducible Factor 1, alpha Subunit
KW - Inhibitor of Apoptosis Proteins
KW - Insulin-Like Growth Factor II
KW - Ki-67 Antigen
KW - Kidney Neoplasms
KW - Matrix Metalloproteinase 1
KW - Microfilament Proteins
KW - Platelet Count
KW - Prognosis
KW - RNA-Binding Proteins
KW - TOR Serine-Threonine Kinases
KW - Tumor Suppressor Protein p53
KW - Vascular Endothelial Growth Factor A
KW - Vimentin
KW - Journal Article
KW - Review
M3 - SCORING: Review article
C2 - 21996985
VL - 63
SP - 293
EP - 308
JO - MINERVA UROL NEFROL
JF - MINERVA UROL NEFROL
SN - 0393-2249
IS - 4
M1 - 4
ER -